Drug Trial Radar · NCT06525220
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
699
Actual
Start
Sep 25, 2024
Primary completion
Jan 2028
Study completion Jul 2030
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
PetosemtamabDrug
MCLA-158
PembrolizumabDrug
Humanized Antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 3 years
- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR)Time frame: Up to approximately 2 years
Locations
202 sites in 28 countries. Site status is shown where the registry gives one.
Site 164
Mobile, Alabama
Site 36
La Jolla, California
Site 27
Los Angeles, California
Site 16
Palo Alto, California
Site 19
Newark, Delaware
Site 108
Washington D.C., District of Columbia
Site 14
Fort Myers, Florida
Site 8
Orlando, Florida
Site 21
St. Petersburg, Florida
Site 20
West Palm Beach, Florida
Site 171
Atlanta, Georgia
Site 197
Chicago, Illinois
Site 50
Chicago, Illinois
Site 2
Louisville, Kentucky
Site 162
Baton Rouge, Louisiana
Site 155
Minneapolis, Minnesota
Site 168
St Louis, Missouri
Site 94
Hackensack, New Jersey
Site 6
Albuquerque, New Mexico
Site 113
Durham, North Carolina
Site 118
Winston-Salem, North Carolina
Site 191
Cleveland, Ohio
Site 43
Philadelphia, Pennsylvania
Site 153
Philadelphia, Pennsylvania
Site 154
Philadelphia, Pennsylvania
Site 89
Chattanooga, Tennessee
Site 115
Memphis, Tennessee
Site 88
Nashville, Tennessee
Site 22
Austin, Texas
Site 1
Houston, Texas
Site 18
Plano, Texas
Site 17
Sugar Land, Texas
Site 15
Tyler, Texas
Site 10
Salt Lake City, Utah
Site 12
Blacksburg, Virginia
Site 23
Norfolk, Virginia
Site 170
CABA, Argentina
Site 96
CABA, Argentina
Site 31
Córdoba, Argentina
Site 30
La Rioja, Argentina
Showing 40 of 202 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.